Anthem Biosciences Ltd IPO has opened for public subscription from 14th July 2025 to 16th July 2025. This is one of the major biotech sector IPOs in 2025 with an issue size of ₹3,395 crore, entirely through an Offer for Sale (OFS). The IPO price band is set at ₹540–₹570 per share, and the Grey Market Premium (GMP) is showing good interest among investors.
In this post, you will find all details about Anthem Biosciences IPO including price, dates, lot size, GMP, financials, strengths, risks, expert reviews, and whether you should subscribe.
IN THIS ARTICLE
About Anthem Biosciences Ltd.
Anthem Biosciences Ltd. is a Bengaluru-based company, founded in 2006. The company operates in the Contract Research, Development, and Manufacturing Organization (CRDMO) space. It serves over 550 global clients across 44 countries, providing services related to:
- Small Molecule Synthesis
- Fermentation-based Active Pharmaceutical Ingredients (APIs)
- Peptides, Probiotics, Nutraceuticals, and Biosimilars
The company has positioned itself as a key player in both drug discovery and manufacturing segments.
Anthem Biosciences Manufacturing Capacity
- Two manufacturing facilities in Bommasandra and Harohalli near Bengaluru.
- Total synthesis capacity: 270 KL
- Total fermentation capacity: 142 KL
- Third facility under development to expand capacity.
Anthem Biosciences IPO Details
| Particular | Details |
|---|---|
| IPO Open Date | 14 July 2025 |
| IPO Close Date | 16 July 2025 |
| Issue Size | ₹3,395 crore (100% OFS) |
| Price Band | ₹540 – ₹570 per share |
| Lot Size | 26 shares |
| Minimum Investment | ₹14,820 (at upper band) |
| Listing on | NSE and BSE |
| Expected Listing Date | 21 July 2025 |
| Anchor Investment | ₹1,016 crore raised |
Important Note:
Since this IPO is a 100% Offer for Sale, no fresh capital will be raised by the company for business expansion. The funds will go to existing shareholders selling their stake.
Anthem Biosciences GMP Today (Grey Market Premium)
GMP or Grey Market Premium reflects investor interest before listing.
- Day 1 GMP: ₹100–₹101
- Day 2 GMP: ₹116
If the upper price band is ₹570 and GMP is ₹116, the estimated listing price could be around ₹686 per share. However, GMP may fluctuate daily, so check live GMP updates closer to the listing date.
Financial Performance of Anthem Biosciences
Anthem Biosciences has shown strong revenue and profit growth over the last three years. Below is a table summarizing its financial performance:
| Financial Year | Revenue | Net Profit (PAT) | EBITDA Margin | Return on Net Worth (RoNW) |
|---|---|---|---|---|
| FY23 | ₹1,133 crore | ₹385 crore | 35% | 18% |
| FY24 | ₹1,500 crore | ₹420 crore | 36% | 19.5% |
| FY25 (Est.) | ₹1,845 crore | ₹451 crore | 37% | 20.8% |
Valuation
- P/E Valuation Range: 67x – 71x on post-IPO FY25 estimated earnings.
- Peer Comparison:
- Syngene International: ~52x P/E
- Divi’s Laboratories: ~83x P/E
- Sai Life Sciences: ~92x P/E
While Anthem Biosciences’ valuation is higher than Syngene but lower than Divi’s and Sai Life, it suggests a fair positioning within the CRDMO sector.
Strengths of Anthem Biosciences IPO
- Integrated CRDMO Platform: From research to manufacturing, the company covers all services under one roof.
- Global Presence: Strong relationships with over 550 clients across 44 countries ensure repeat business.
- Profitability: Consistent margins of 35–37% over recent years with strong return ratios.
- Capacity Expansion: Third manufacturing unit being developed, showing long-term growth planning.
- Anchor Investor Interest: ₹1,016 crore already raised from leading institutional investors indicates trust in the company.
Risks and Weaknesses
- 100% OFS: No funds raised for expansion could be a negative for growth-focused investors.
- High Valuation: P/E ratio above sector average may not appeal to value investors.
- Sector Dependency: Regulatory and market risks linked to the pharmaceutical and biotech sector could impact future growth.
- Concentration Risk: Heavy reliance on certain major clients and specific business verticals.
Expert Reviews and Recommendations
Brokerage House Opinions
- SBI Securities: Recommended subscribing based on strong fundamentals and global client base.
- Anand Rathi: Positive on integrated model and margin consistency.
- Kejriwal Research: Subscribe recommendation citing fair valuation and sector growth opportunity.
Analyst Conclusion
Anthem Biosciences IPO is attracting good interest both in retail and institutional categories. Subscription status as of Day 2 showed:
- QIB: Leading interest (50% quota).
- NII: Actively participating (15% quota).
- Retail: Steady response (35% quota).
This suggests a healthy overall subscription figure. Experts believe long-term investors in the healthcare and biotech sector may find this IPO attractive despite its valuation premium.
Should You Apply for Anthem Biosciences IPO?
Who Should Consider Applying:
- Investors looking for exposure to India’s growing pharma and biotech outsourcing industry.
- Long-term investors focused on companies with global scale and profitability.
- Investors comfortable with medium-to-high valuation stocks.
Who Should Be Careful:
- Investors preferring IPOs with fresh capital raising (not just OFS).
- Conservative investors looking for low P/E IPOs.
- Traders seeking short-term listing gains without considering long-term fundamentals.
How to Apply for Anthem Biosciences IPO?
You can apply through:
- UPI-based applications via Zerodha, Groww, Angel One, Paytm Money, etc.
- ASBA service through your net banking portal (ICICI, HDFC, SBI, etc.).
Minimum lot size: 26 shares
Investment amount per lot: ₹14,820 (at the upper price band).
FAQ: Anthem Biosciences IPO
What is Anthem Biosciences IPO GMP today?
GMP is approximately ₹116 as of 15th July 2025.
What is the IPO price band?
The price band is ₹540 to ₹570 per equity share.
Is Anthem Biosciences IPO a good investment?
For long-term investors interested in the biotech and pharmaceutical sector, many experts recommend subscribing. Valuation is slightly high but justified by company performance.
Disclaimer: This content is for informational purposes only. It is not investment advice. Please consult a financial advisor before making any investment decisions.
